In the last trading session, 1.12 million shares of the EyePoint Pharmaceuticals Inc (NASDAQ:EYPT) were traded, and its beta was 1.40. Most recently the company’s share price was $6.49, and it changed around -$0.13 or -1.89% from the last close, which brings the market valuation of the company to $443.29M. EYPT currently trades at a discount to its 52-week high of $30.99, offering almost -377.5% off that amount. The share price’s 52-week low was $6.55, which indicates that the current value has fallen by an impressive -0.92% since then. We note from EyePoint Pharmaceuticals Inc’s average daily trading volume that its 10-day average is 1.0 million shares, with the 3-month average coming to 896.43K.
EyePoint Pharmaceuticals Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.08. If we narrow it down even further, the data shows that 0 out of 13 analysts rate the stock as a Sell; another 4 rate it as Overweight. Among the rest, 0 recommended EYPT as a Hold, whereas 9 deemed it a Buy, and 0 rated it as Underweight. EyePoint Pharmaceuticals Inc is expected to report earnings per share of -0.48 for the current quarter.
EyePoint Pharmaceuticals Inc (NASDAQ:EYPT) trade information
Instantly EYPT has showed a red trend with a performance of -1.89% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 8.68 on recent trading dayincreased the stock’s daily price by 25.23%. The company’s shares are currently down -12.82% year-to-date, but still down -15.10% over the last five days. On the other hand, EyePoint Pharmaceuticals Inc (NASDAQ:EYPT) is -29.56% down in the 30-day period. We can see from the shorts that 10.58 million shares have been sold at a short interest cover period of 11.81 day(s).
The consensus price target as assigned by Wall Street analysts is $22, which translates to bulls needing to increase their stock price by 70.5% from its current value. Analyst projections state that EYPT is forecast to be at a low of $22 and a high of $22.
EyePoint Pharmaceuticals Inc (EYPT) estimates and forecasts
The year-over-year growth rate is expected to be -7.55%, down from the previous year.
Consensus estimates provided by 12 financial analysts predict the company will bring in an average of 11.02M in revenue for the current quarter. 7 analysts expect EyePoint Pharmaceuticals Inc to make 7.05M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 14.03M and 11.68M respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -21.42%. Forecasts for the next quarter put sales growth at -39.64%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 29.57%. EyePoint Pharmaceuticals Inc earnings are expected to increase by -19.37% in 2025, but the outlook is negative -15.63% per year for the next five years.
EYPT Dividends
EyePoint Pharmaceuticals Inc’s next quarterly earnings report is expected to be released in March.
EyePoint Pharmaceuticals Inc (NASDAQ:EYPT)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 1.16% of EyePoint Pharmaceuticals Inc shares, and 96.15% of them are in the hands of institutional investors. The stock currently has a share float of 97.27%. EyePoint Pharmaceuticals Inc stock is held by 210.0 institutions, with CORMORANT ASSET MANAGEMENT, LP being the largest institutional investor. By 2024-06-30, it held 15.7334% of the shares, which is about 8.32 million shares worth $72.43 million.
SUVRETTA CAPITAL MANAGEMENT, LLC, with 9.7818% or 5.18 million shares worth $45.03 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Federated Hermes Kaufmann Fund and Federated Hermes Kaufmann Small Cap Fund were the top two Mutual Funds as of Oct 31, 2024 . The former held 2.04 shares worth $13.24 million, making up 2.99% of all outstanding shares. On the other hand, Federated Hermes Kaufmann Small Cap Fund held roughly 1.61 shares worth around $10.46 million, which represents about 2.36% of the total shares outstanding.
